Financial Perspectives’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Financial Perspectives’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-250	Closed	-$55	–	713
2023 Q2	$55	Hold	250	–	–	﹤0.01%	674
2023 Q1	$79	Hold	250	–	–	﹤0.01%	670
2022 Q4	$295	Hold	250	–	–	﹤0.01%	655
2022 Q3	$233	Hold	250	–	–	﹤0.01%	672
2022 Q2	$275	Hold	250	–	–	﹤0.01%	667
2022 Q1	$440	Hold	250	–	–	﹤0.01%	662
2021 Q4	$583	Hold	250	–	–	﹤0.01%	625
2021 Q3	$920	Hold	250	–	–	﹤0.01%	619
2021 Q2	$1.85K	Sell	250 -1,225	-83%	-$7.65K	﹤0.01%	612
2021 Q1	$250K	Buy	1,475 +1,225	+490%	+$8.28K	0.01%	376
2020 Q4	$1.52K	Hold	250	–	–	﹤0.01%	559
2020 Q3	$1.77K	Hold	250	–	–	﹤0.01%	503
2020 Q2	$1.66K	Buy	+250	New	+$1.73K	﹤0.01%	493

Other funds holding ARDS

Wealth Architects Mountain View, California $1.27B AUM 36.93% 1-Year Est. Return

Financial Perspectives's ARDS Position: Q3 2023 in Review

Financial Perspectives sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 250 shares — an estimated $55 sold.

Financial Perspectives first reported a position in ARDS in Q2 2020 and held it in 13 quarters. The position peaked at $250K in Q1 2021. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.

Financial Perspectives reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Financial Perspectives sold 250 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $55.
Financial Perspectives first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q2 2020 and held it in 13 quarters.
Financial Perspectives's Aridis Pharmaceuticals Inc. Common Stock position peaked at $250K in Q1 2021.
1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on Financial Perspectives's 13F filing for Q3 2023, filed 10 Jan 2024.